

Federico Lussana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5511421/publications.pdf>

Version: 2024-02-01

62
papers

2,871
citations

257357

24
h-index

168321

53
g-index

62
all docs

62
docs citations

62
times ranked

4189
citing authors

#	ARTICLE	IF	CITATIONS
1	Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1&JAK2 positive myeloid sarcoma and acute B&lymphoblastic leukemia. Clinical Case Reports (discontinued), 2022, 10, e05212.	0.2	7
2	Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leukemia and Lymphoma, 2021, 62, 1490-1496.	0.6	37
3	Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell"Redirected Bispecific Antibodies. Journal of Clinical Oncology, 2021, 39, 444-455.	0.8	18
4	MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL. Cancers, 2021, 13, 2108.	1.7	5
5	Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021057.	0.5	7
6	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. Haematologica, 2021, 106, 2578-2587.	1.7	15
7	ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report. Blood, 2021, 138, 216-216.	0.6	0
8	Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT. Blood, 2021, 138, 472-472.	0.6	2
9	Evaluation of platelet function in essential thrombocythemia under different analytical conditions. Platelets, 2020, 31, 179-186.	1.1	12
10	National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?. BMC Cancer, 2020, 20, 956.	1.1	1
11	Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T&cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. American Journal of Hematology, 2020, 95, 1466-1472.	2.0	42
12	High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG). Cancers, 2020, 12, 2242.	1.7	5
13	Sleeping Beauty"engineered CAR T cells achieve antileukemic activity without severe toxicities. Journal of Clinical Investigation, 2020, 130, 6021-6033.	3.9	102
14	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). Biology of Blood and Marrow Transplantation, 2019, 25, 2388-2397.	2.0	33
15	Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia. Cancers, 2019, 11, 1455.	1.7	20
16	A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML. Blood, 2019, 134, 3855-3855.	0.6	4
17	Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06. Blood, 2019, 134, 1443-1443.	0.6	1
18	Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2019, 134, 200-200.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Treatment of Elderly Patients with Acute Promyelocytic Leukemia: A Real Life Experience of the "Rete Ematologica Lombarda". <i>Blood</i> , 2019, 134, 3862-3862.	0.6	0
20	Ruxolitinib-associated infections: A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2018, 93, 339-347.	2.0	164
21	Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study. <i>Blood</i> , 2018, 132, 3404-3404.	0.6	1
22	Thrombosis prophylaxis in pediatric liver transplantation: A systematic review. <i>World Journal of Hepatology</i> , 2018, 10, 752-760.	0.8	16
23	Heparin-like effect resistant to protamine in a child with haemorrhagic shock. Do we need heparinase?. <i>Blood Transfusion</i> , 2018, 16, 394-396.	0.3	4
24	Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. <i>Journal of Hematology and Oncology</i> , 2017, 10, 54.	6.9	41
25	Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies. <i>Expert Review of Hematology</i> , 2017, 10, 627-636.	1.0	0
26	Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2070-2078.	2.0	48
27	Inflammation and myeloproliferative neoplasms. <i>Journal of Autoimmunity</i> , 2017, 85, 58-63.	3.0	102
28	Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review. <i>Internal and Emergency Medicine</i> , 2016, 11, 467-476.	1.0	1
29	Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1983-1987.	2.0	77
30	Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation. <i>Blood</i> , 2016, 128, 1160-1160.	0.6	5
31	Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty. <i>Thrombosis and Haemostasis</i> , 2015, 114, 237-244.	1.8	2
32	Effects of chronic administration of valproic acid to epileptic patients on coagulation tests and primary hemostasis. <i>Epilepsia</i> , 2015, 56, e49-52.	2.6	19
33	Effect of prasugrel in patients with asthma: results of PRINA, a randomized, double-blind, placebo-controlled, crossover study. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 136-141.	1.9	34
34	Levels of Minimal Residual Disease Prior to Transplant Influence Outcome of Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 4374-4374.	0.6	0
35	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythemia vera. <i>British Journal of Haematology</i> , 2014, 167, 541-546.	1.2	47
36	A systematic review on the effect of aspirin in the prevention of post-operative arterial thrombosis in patients undergoing total hip and total knee arthroplasty. <i>Thrombosis Research</i> , 2014, 134, 599-603.	0.8	22

#	ARTICLE	IF	CITATIONS
37	Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. <i>American Journal of Hematology</i> , 2014, 89, 306-309.	2.0	50
38	Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 916-921.	1.7	62
39	ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014065.	0.5	8
40	Evaluation of the prevalence of severe hyperhomocysteinemia in adult patients with thrombosis who underwent screening for thrombophilia. <i>Thrombosis Research</i> , 2013, 132, 681-684.	0.8	16
41	Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1183-1189.	1.9	398
42	Pregnancy-related venous thromboembolism: Risk and the effect of thromboprophylaxis. <i>Thrombosis Research</i> , 2012, 129, 673-680.	0.8	49
43	Prevalence of factor V Leiden and G20210A prothrombin mutation in the Dutch Famine Birth Cohort: A possible survival advantage?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 399-401.	1.8	7
44	The impact of perioperative transfusion of blood products on survival after pediatric liver transplantation. <i>Pediatric Transplantation</i> , 2012, 16, 357-366.	0.5	45
45	Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2011, 118, 3359-3366.	0.6	49
46	Can plasma levels of N-terminal pro-brain natriuretic peptide be useful in predicting the risk of developing chronic pulmonary hypertension in patients with pulmonary embolism?. <i>Internal and Emergency Medicine</i> , 2009, 4, 443-444.	1.0	0
47	Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review. <i>Thrombosis Research</i> , 2009, 124, 409-417.	0.8	156
48	Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). <i>Thrombosis Research</i> , 2009, 124, e1-e5.	0.8	15
49	Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). <i>Thrombosis Research</i> , 2009, 124, e19-e25.	0.8	48
50	Polymorphisms of the Z protein protease inhibitor and risk of venous thromboembolism: a meta-analysis. <i>British Journal of Haematology</i> , 2008, 143, 284-287.	1.2	11
51	Prenatal exposure to the Dutch famine is associated with a preference for fatty foods and a more atherogenic lipid profile. <i>American Journal of Clinical Nutrition</i> , 2008, 88, 1648-1652.	2.2	217
52	Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. <i>Haematologica</i> , 2007, 92, 694-697.	1.7	128
53	Venous Thrombosis at Unusual Sites and the Role of Thrombophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 582-587.	1.5	23
54	Abnormalities of homocysteine and B vitamins in the nephrotic syndrome. <i>Thrombosis Research</i> , 2007, 120, 647-652.	0.8	17

#	ARTICLE	IF	CITATIONS
55	Usefulness of Pfa-100® testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2393-2398.	1.9	99
56	A rare case of autoimmune haemolytic anaemia due to warm IgA autoantibodies with reticulocytopenia. <i>Internal and Emergency Medicine</i> , 2007, 2, 153-156.	1.0	2
57	Association of estrogen receptor-alpha genepolymorphisms with venous thrombosis. <i>Haematologica</i> , 2006, 91, 279-80.	1.7	13
58	Are the Pfa-100® Closure Time and the Skin Bleeding Time Useful in the Diagnostic Work-Up of Patients with Bleeding Diathesis? Correlation with the Severity of Bleeding Symptoms and Sensitivity for Known Defects of Primary Hemostasis.. <i>Blood</i> , 2004, 104, 3037-3037.	0.6	1
59	Association of factor V deficiency with factor V HR2. <i>Haematologica</i> , 2004, 89, 195-200.	1.7	14
60	Blood levels of homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives compared to non-users. <i>Thrombosis Research</i> , 2003, 112, 37-41.	0.8	56
61	Hyperhomocysteinemia and cardiovascular aging. <i>Advances in Cell Aging and Gerontology</i> , 2002, 11, 309-335.	0.1	0
62	Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. <i>Blood</i> , 2001, 98, 2730-2735.	0.6	488